Key facts
- Modafinil for idiopathic hypersomnia in one line: it is not FDA-approved for idiopathic hypersomnia (IH), but US sleep specialists often use it off-label, and the American Academy of Sleep Medicine gives it a strong recommendation for adults with IH. See our modafinil overview for the basics.
- The only FDA-approved medicine for IH in adults is Xywav, a low-sodium oxybate (Schedule III, available only through a restricted program).
- For ADHD, modafinil is not FDA-approved. A large trial in adults found no benefit over placebo, and pediatric trials raised serious skin-rash concerns.
- For multiple sclerosis (MS) fatigue, the best US trial found modafinil worked no better than placebo, although it may help MS-related sleepiness in some people.
- Modafinil is a Schedule IV controlled substance and needs a prescription from a licensed prescriber who has evaluated you.
If you live with constant sleepiness that sleep does not fix, you may have come across modafinil for idiopathic hypersomnia, ADHD or MS fatigue. Modafinil is FDA-approved for just three conditions: narcolepsy, obstructive sleep apnea and shift work disorder. Everything else is “off-label,” meaning a prescriber can choose to use it when they judge the benefits worth the risks, but the FDA has not reviewed the evidence for that use.
The evidence is very different across these three conditions. This guide walks through what the studies show for each, how off-label prescribing works in the US, and what to ask your prescriber. If you are new to the medicine, start with our modafinil pillar guide, and for the approved use, see modafinil for narcolepsy.
What the FDA label covers, and what “off-label” means
The FDA prescribing information states that modafinil “is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD)” (Provigil prescribing information, FDA). MedlinePlus lists the same three uses and notes that the medicine “may be prescribed for other uses.”
Off-label prescribing is legal in the US and common in sleep medicine. It does have practical effects for you: insurers are more likely to require prior authorization or deny coverage, and the label’s dosing and safety data come from people with the approved conditions, not from your condition.
Modafinil for idiopathic hypersomnia: what the evidence says
Idiopathic hypersomnia is an uncommon sleep disorder that causes excessive daytime sleepiness “despite adequate quantity and normal quality of sleep at night,” according to the AASM’s Sleep Education page on IH. People often sleep longer than average, struggle to wake up, feel confused or “drunk” after waking (sleep inertia), and take long naps that do not refresh them. Unlike narcolepsy, there is no cataplexy.
The clinical trials
Only a handful of controlled trials exist, but they point in the same direction:
- A 2021 randomized, placebo-controlled trial at 20 centers in Japan gave 71 adults with IH either modafinil 200 mg each morning or placebo for three weeks. On the Maintenance of Wakefulness Test, the modafinil group stayed awake about 5 minutes longer on average than the placebo group. Side effects were more common with modafinil (59% vs 27%), mainly headache, dry mouth and nausea (Inoue et al., Sleep Medicine, 2021). The study was funded by the drug’s Japanese marketer.
- A French cohort of 104 people with IH and 126 with narcolepsy found modafinil produced a similar drop in Epworth Sleepiness Scale scores in both groups, with nervousness, palpitations and headache as the most common complaints in IH (Lavault et al., Sleep Medicine, 2011).
- In a small crossover study of 27 people with narcolepsy or IH, modafinil reduced lane drifting during real on-road driving compared with placebo (Philip et al., Sleep, 2014).
Real-world US data are similar. In a Mayo Clinic review of 85 people with IH, 65% had a “complete response” to medication; modafinil and methylphenidate were the most used, and the authors found no significant difference between them (Ali et al., Journal of Clinical Sleep Medicine, 2009).
Where modafinil fits in US guidelines
The AASM’s 2021 guideline on central disorders of hypersomnolence makes modafinil the only medicine with a strong recommendation for adults with IH. Clarithromycin, methylphenidate, pitolisant and sodium oxybate get conditional recommendations, mostly based on very low-quality evidence (AASM guideline at a glance).
Meanwhile, Xywav (calcium, magnesium, potassium and sodium oxybates) is the medicine FDA-approved “for the treatment of idiopathic hypersomnia (IH) in adults.” It carries a boxed warning for central nervous system depression and abuse, is Schedule III, and is available only through the XYWAV and XYREM REMS program (Xywav label, DailyMed).
| Option for adult IH | FDA-approved for IH? | AASM 2021 rating | DEA schedule |
|---|---|---|---|
| Modafinil | No (off-label) | Strong | IV |
| Low-sodium oxybate (Xywav) | Yes | Conditional (sodium oxybate) | III |
| Methylphenidate | No | Conditional | II |
| Pitolisant | No | Conditional | Not controlled |
| Clarithromycin | No | Conditional | Not controlled |
Getting the diagnosis right comes first. IH is diagnosed with an overnight sleep study followed by a Multiple Sleep Latency Test the next day, and only after other causes of sleepiness are ruled out, such as sleep apnea, insufficient sleep, depression or medicines. The same testing route is covered in our guide to getting modafinil legally.
Modafinil for ADHD: why it isn’t approved
Modafinil’s alerting effect led researchers to test it for ADHD, but the results did not hold up:
- In a 9-week trial of 330 adults with ADHD, no dose of modafinil beat placebo on the main ADHD symptom score. The authors concluded it “did not demonstrate a benefit on ADHD symptoms in adults” (Arnold et al., Journal of Attention Disorders, 2014).
- In the pediatric ADHD program, the FDA label reports “3 cases of serious rash including one case of possible SJS among 933 patients exposed to modafinil”, and states that modafinil “is not approved for use in pediatric patients for any indication” (FDA label). SJS (Stevens-Johnson syndrome) is a rare, life-threatening skin reaction.
For ADHD, FDA-approved stimulants and non-stimulants remain the standard. Our modafinil vs Adderall comparison explains how these medicines differ, including their controlled-substance schedules.
Modafinil for MS fatigue: sleepiness vs fatigue
Fatigue is one of the most common and disabling MS symptoms, and modafinil has been prescribed for it for years. The research is mixed, and the newest and best-designed trial is negative:
- An early US study of 72 people with MS reported less fatigue on modafinil, but it was single-blind and compared each person with their own placebo run-in (Rammohan et al., 2002).
- A double-blind French trial of 115 people found no difference from placebo on fatigue (Stankoff et al., Neurology, 2005).
- The TRIUMPHANT-MS trial at Johns Hopkins and UCSF, funded by the Patient-Centered Outcomes Research Institute, tested amantadine, modafinil, methylphenidate and placebo in 141 people. None beat placebo, and all three medicines caused more side effects. The authors wrote that the results “do not support an indiscriminate use” of these drugs for MS fatigue (Nourbakhsh et al., Lancet Neurology, 2021).
There is one important nuance. Fatigue (lack of energy) is not the same as sleepiness (falling asleep easily). The AASM gives a conditional suggestion for modafinil for hypersomnia caused by MS, based on very low-quality evidence. So a prescriber may still consider it for measured excessive sleepiness, after checking for treatable causes like sleep apnea, depression, poor sleep from pain or bladder symptoms, and medicine side effects.
When to get help now: stop modafinil and get emergency care (call 911) for any rash with blistering, peeling or mouth sores, swelling of the face, lips or throat, trouble breathing, chest pain, or a fast or irregular heartbeat. Call 988 for thoughts of suicide or severe mood changes. For a possible overdose, call Poison Help at 1-800-222-1222. Never drive if you still feel sleepy. More detail is in our modafinil side effects guide.
Questions to ask your prescriber
- Has my sleepiness been confirmed with a sleep study and MSLT, and have sleep apnea and other causes been ruled out?
- Is modafinil off-label for my condition, and what does the evidence show for people like me?
- Would an FDA-approved option, such as Xywav for IH, be a better fit, and what are its risks?
- How will we measure whether it is working, and when do we stop if it isn’t?
- Will my insurance need prior authorization, and what happens if it is denied?
- Does modafinil interact with my other medicines, including hormonal birth control? (Modafinil can make it less effective.)
Remember: modafinil is a Schedule IV prescription medicine, so in the US it can only be dispensed by a licensed pharmacy against a valid prescription from a prescriber who has evaluated you.
Frequently asked questions
Is modafinil FDA-approved for idiopathic hypersomnia?
No. Modafinil is FDA-approved only for excessive sleepiness from narcolepsy, obstructive sleep apnea and shift work disorder. Doctors can prescribe it off-label for idiopathic hypersomnia, and the AASM strongly recommends it for adults with IH. Xywav is the FDA-approved IH medicine.
Does modafinil work for idiopathic hypersomnia?
Randomized trials and clinic studies show it improves daytime sleepiness for many adults with IH, with benefits similar to those seen in narcolepsy. It does not cure IH, and headache, nausea and nervousness are common side effects.
Can modafinil be used for ADHD?
It is not FDA-approved for ADHD. A large adult trial found no benefit over placebo, and pediatric trials reported serious skin rashes. FDA-approved ADHD medicines are the standard choice.
Does modafinil help MS fatigue?
The strongest US trial found modafinil worked no better than placebo for MS fatigue and caused more side effects. It may still help some people whose main problem is excessive sleepiness rather than fatigue, which is a decision to make with a neurologist or sleep specialist.
Related guides
- Modafinil Explained: Uses, How It Works and Safety
- Modafinil for Narcolepsy: How It Treats Excessive Daytime Sleepiness
- Modafinil Side Effects: Common, Rare and When to Get Help
- Modafinil vs Armodafinil: What’s the Difference?
- Modafinil vs Adderall (and Vyvanse, Ritalin): How They Differ
- How to Buy Modafinil for Narcolepsy Treatment (Prescription Required)
- Is Modafinil a Controlled Substance? Schedule IV Explained
- How Modafinil Works: Mechanism, Half-Life and How Long It Lasts
- Modafinil Dosage: What the FDA Label Says
- Modafinil Interactions: Alcohol, Birth Control and Caffeine
- The “Smart Drug” Myth: Modafinil in Healthy People
- How to Get a Modafinil Prescription: Sleep Studies, Telehealth and Insurance
Sources
- FDA. Provigil (modafinil) prescribing information, revised 01/2015.
- MedlinePlus. Modafinil (revised 07/20/2024).
- American Academy of Sleep Medicine, Sleep Education. Idiopathic hypersomnia.
- AASM. Treatment of Central Disorders of Hypersomnolence: guideline at a glance (Maski et al., J Clin Sleep Med, 2021).
- DailyMed. Xywav (calcium, magnesium, potassium, and sodium oxybates) label, revised 7/2025.
- Inoue Y, et al. Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long sleep time. Sleep Med. 2021.
- Lavault S, et al. Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Med. 2011.
- Philip P, et al. Modafinil improves real driving performance in patients with hypersomnia. Sleep. 2014.
- Ali M, et al. Idiopathic hypersomnia: clinical features and response to treatment. J Clin Sleep Med. 2009.
- Arnold VK, et al. Modafinil as treatment for adults with ADHD. J Atten Disord. 2014.
- Rammohan KW, et al. Modafinil for the treatment of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002.
- Stankoff B, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005.
- Nourbakhsh B, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis. Lancet Neurol. 2021.
